뇌졸중 치료 연구의 한계점과 도전: 기초 및 중개 뇌졸중 연구 최신지견
Challenges and Pitfalls of Stroke Therapeutics Research
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Ischemia-reperfusion injury is complicated with multiple injury pathways. If a particular agent is used to restore blood flow and prevent cell death, many damaged neurons may come back to life. However, for stroke victims, there are no effective curative therapeutic approaches available other than thrombolytic treatment. The efficacy of neuroprotective agents are limited by low diffusion, narrow time window, strict dose titration, and lack of confidence at the preclinical level. NXY-059 reflects the fundamental limitation of neuroprotectant. There are recent attempts to overcome these limitations, with use of annexin A2, fingolimod, hydrogen, nitrite, and more. By covering two components, this report reviews what we have recently learned. In addition, it sheds light on some of the newer issues in clinical application. (Korean J Stroke 2011;13:11-15)
Abstract
Ischemia-reperfusion injury is complicated with multiple injury pathways. If a particular agent is used to restore blood flow and prevent cell death, many damaged neurons may come back to life. However, for stroke victims, there are no effective curative therapeutic approaches available other than thrombolytic treatment. The efficacy of neuroprotective agents are limited by low diffusion, narrow time window, strict dose titration, and lack of confidence at the preclinical level. NXY-059 reflects the fundamental limitation of neuroprotectant. There are recent attempts to overcome these limitations, with use of annexin A2, fingolimod, hydrogen, nitrite, and more. By covering two components, this report reviews what we have recently learned. In addition, it sheds light on some of the newer issues in clinical application. (Korean J Stroke 2011;13:11-15)
참고문헌 (23)
- Shuaib A, "NXY-059 for the treatment of acute ischemic stroke", N Engl J Med, 357, pp.562~571 (2007)
- Macleod MR, "Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality", Stroke, 39, pp.2824~2829 (2008)
- Minnerup J, "The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis", Stroke, 40, pp.3113~3120 (2009)
- Ehrenreich H, "Recombinant human erythropoietin in the treatment of acute ischemic stroke", Stroke, 40, pp.e647~e656 (2009)
- Jerndal M, "A systematic review and meta-analysis of erythropoietin in experimental stroke", J Cereb Blood Flow Metab, 30, pp.961~968 (2010)
- Pfeffer MA, "A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease", N Engl J Med, 361, pp.2019~2032 (2009)
- Solomon SD, "Erythropoietic response and outcomes in kidney disease and type 2 diabetes", N Engl J Med, 363, pp.1146~1155 (2010)
- Minnerup J, "Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia", Stroke, 39, pp.1855~1861 (2008)
- Schäbitz WR, "AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke", Stroke, 41, pp.2545~2551 (2010)
- van der Worp HB, "Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials", J Cereb Blood Flow Metab, 30, pp.1079~1093 (2010)
- Hemmen TM, "Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results", Stroke, 41, pp.2265~2270 (2010)
- Su EJ, "Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke", Nat Med, 14, pp.731~737 (2008)
- Fan X, "Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy", Stroke, 41, pp.S54~S58 (2010)
- Zhu H, "Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke", J Cereb Blood Flow Metab, 30, pp.1137~1146 (2010)
- Yemisci M, "Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery", Nat Med, 15, pp.1031~1037 (2009)
- Hasegawa Y, "Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats", Stroke, 41, pp.368~374 (2010)
- Wei Y, "Fingolimod provides long-term protection in rodent models of cerebral ischemia", Ann Neurol, 69, pp.119~129 (2011)
- Domínguez C, "Santamarina E, et al. Oxidative stress after thrombolysis-induced reperfusion in human stroke", Stroke, 41, pp.653~660 (2010)
- Wood KC, "The hydrogen highway to reperfusion therapy", Nat Med, 13, pp.673~674 (2007)
- Ohsawa I, "Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals", Nat Med, 13, pp.688~694 (2007)
- Duranski MR, "Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver", J Clin Invest, 115, pp.1232~1240 (2005)
- Jung KH, "Early intravenous infusion of sodium nitrite protects brain against in vivo ischemia-reperfusion injury", Stroke, 37, pp.2744~2750 (2006)
- Jung KH, "Augmentation of nitrite therapy in cerebral ischemia by NMDA receptor inhibition", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 378(3), pp.507~512, ACADEMIC PRESS INC ELSEVIER SCIENCE